Hasil Pencarian - Daniel Rayson

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center

    Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center oleh John Loggie, Penelope J. Barnes, Michael D. Carter, Daniel Rayson, Gillian C. Bethune

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients.

    Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. oleh Arik Drucker, Evelyn M Teh, Ripsik Kostyleva, Daniel Rayson, Susan Douglas, Devanand M Pinto

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

    Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective oleh Jan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, Stephen Chia, Shane Shapera, Micheal McInnis, Daniel Rayson, Jamil Asselah

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review

    Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review oleh Margaret Sheridan, Bruce Colwell, Nathan W. D. Lamond, Robyn Macfarlane, Daniel Rayson, Stephanie Snow, Lori A. Wood, Ravi Ramjeesingh

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain

    Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain oleh Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895”

    Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Canc... oleh Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

    Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines oleh Christine Simmons, Daniel Rayson, Anil Abraham Joy, Jan-Willem Henning, Julie Lemieux, Heather McArthur, Paul B. Card, Rebecca Dent, Christine Brezden-Masley

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: